AstraZeneca's CLDN18.2-targeting ADC doubles survival period in Phase 3 trial, Refuge Biotech also in focus
Predicted impact: Low
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.
Predicted impact: Low
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.